IMCR News & Events

Reports Q4 revenue $104.5M, consensus $107.77M. "With $400 million in KIMMTRAK sales and a diverse clinical portfolio, Immunocore had a productive year of growth and progress in 2025," said Bahija Jallal, CEO of Immunocore. "Our priority for 2026 is the clear execution of our clinical trials, particularly as we anticipate key data in oncology and begin our first trial in autoimmune disease. We remain focused on the long-term goal of developing medicines that can significantly improve patient lives."

Immunocore Holdings announced that Dr. David Berman, Executive Vice President, EVP, Research and Development, will leave the Company effective 27 February 2026. Dr. Berman has accepted a Development Head role at a large commercial-stage biotech company. Immunocore does not intend to seek a direct replacement for Dr. Berman and will instead streamline its R&D structure and leverage the existing experienced leadership team. The Company is promoting Dr. Mohammed Dar, its current Chief Medical Officer, and Mark Moyer, its current Head of Regulatory Sciences, to Executive Vice President roles, assuming expanded oversight of clinical development and regulatory strategies.

Immunocore set out its strategic priorities for 2026 including its plans for reaching more patients with melanoma and other diseases with high unmet needs. The Company highlights the potential of its melanoma franchise building on KIMMTRAK's performance including the completion of enrollment in TEBE-AM, the registrational late-line cutaneous melanoma trial, in the first half of this year. In addition to enrolling patients in three Phase 3 trials, the Company expects to present data from multiple Phase 1/2 trials in 2026. "2026 will be an important year for Immunocore. We are building a leading melanoma franchise - first with KIMMTRAK, the standard of care for HLA-A*02:01-positive patients with metastatic uveal melanoma, and next in cutaneous melanoma through the TEBE-AM Phase 3 trial, which is our top priority for 2026," said Bahija Jallal, CEO of Immunocore. "We expect to complete enrollment in the first half, positioning us for data readout as early as the second half of the year. We also continue to advance our broad pipeline, with pivotal readouts in oncology and infectious diseases, and dosing of the first patient in our first autoimmune trial this year."